Pre-made Gontivimab benchmark antibody ( Bispecific Single Domains (VH-VH'-VH'), anti-RSV gpF therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Gontivimab benchmark antibody (Bispecific Single Domains (VH-VH'-VH'), anti-RSV gpF therapeutic antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Gontivimab is a monoclonal antibody-derived therapeutic protein (Nanobodies®) (designated as ALX 0171), being developed by Ablynx (a subsidiary of Sanofi) as a once-daily treatment of patients with respiratory syncytial virus (RSV) infections.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-251-1mg	1mg	Inquiry
GMP-Bios-ab-251-10mg	10mg	Inquiry
GMP-Bios-ab-251-100mg	100mg	Inquiry
GMP-Bios-ab-251-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Gontivimab biosimilar, Bispecific Single Domains (VH-VH'-VH’): Anti-RSV gpF therapeutic antibody
INN Name	Gontivimab
Target	RSV gpF
Format	Bispecific Single Domains (VH-VH'-VH')
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	na
VD LC	na
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2019
Year Recommended	2020
Companies	Ablynx
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Respiratory syncytial virus infections
Development Tech	na